ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biogen Idec has reached an agreement with Carl Icahn, naming one of Icahn’s nominees to its board. In exchange, the activist investor dropped a threatened proxy fight. The biopharmaceutical firm appointed Eric K. Rowinsky and Stephen A. Sherwin to the board to replace outgoing members James C. Mullen and Bruce R. Ross. Rowinsky is one of three people Icahn has been attempting to put on the board since early last year in an effort to sell or break up Biogen. “The nominees who will replace Messrs. Mullen and Ross are extremely qualified and I believe will add great value to Biogen,” Icahn said in a statement./p>
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter